Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

9.980 -0.160 (-1.58%)
Delayed Quote Updated: 10:33 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
News headline image
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study ↗
 
Via Benzinga
News headline image
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Buyback siRNA Complement Assets
From Silence Therapeutics plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 15, 2023 ↗
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
News headline image
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
From Silence Therapeutics
Via Business Wire
News headline image
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Silence Therapeutics
Via Business Wire
News headline image
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
News headline image
Silence Therapeutics Reports Third Quarter 2022 Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Silence Therapeutics Gets FDA Fast Track Status For Blood Cancer Candidate ↗
Silence Therapeutics  (NASDAQ: SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera... 
Via Benzinga
News headline image
Silence Therapeutics to Participate in September Investment Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Workday, Electronic Arts, Ulta Beauty And Some Other Big Stocks Moving Higher On Friday ↗
  Micro Focus International plc (NYSE: MFGP) shares jumped 95.4% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
News headline image
Silence Therapeutics Announces Pricing of Underwritten Offering
From Silence Therapeutics plc
Via Business Wire
News headline image
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
News headline image
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
News headline image
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.